Clinical ophthalmology (Auckland, N.Z.)最新文献

{"title":"Efficacy and Safety of Cataract Surgery Combined with Ab Interno Canaloplasty and Micro-Trabecular Bypass Stent Surgery in Open-Angle Glaucoma.","authors":"Matthew S Porter, Addie Flowers, Brandon P Wood, Mark J Gallardo","doi":"10.2147/OPTH.S504247","DOIUrl":"https://doi.org/10.2147/OPTH.S504247","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the effectiveness of canaloplasty via an ab-interno technique using the iTrack (Nova Eye Medical, Fremont, USA) combined with microtrabecular bypass stent surgery with the Hydrus microstent (Ivantis, Inc, Irvine, CA) following cataract surgery (CE) in patients with primary open-angle glaucoma (POAG).</p><p><strong>Methods: </strong>A retrospective, two-center, case series of 51 POAG eyes that underwent phacoemulsification followed by canaloplasty combined with microtrabecular bypass stent surgery. Eyes were categorized according to IOP and disease severity. A subgroup of patients on 3+ medications at baseline was included. Primary end points included the mean IOP and mean number of medications at 12 months, 24 months and at the last follow-up.</p><p><strong>Results: </strong>Baseline IOP (mmHg) and number of medications were 19.1±4.0 and 2.3±1.2 and reduced to 13.9±2.6 (p<0.001) and 1.2±1.4 (p<0.001) at 12 months, 13.7±2.0 and 1.5±1.5 (p<0.001, p=0.008, respectively) at 24 months (n=31) and 14.4±3.2 and 2.1±1.5 (p<0.001, p=0.5, respectively) at 36 months. In the uncontrolled group (n=27), baseline IOP and number of medications were 21.9±3.1 and 1.9±1.3 and reduced to 14.6±4.2 (p=0.006) and 1.7±1.6 (p=0.821) at 36 months postoperatively. Baseline IOP and number of medications of severe patients (n=12) were 19.0±4.8 and 1.9±1.1. IOP reduced to 12.8±2.4 (p=0.005) at 12 months while the number of medications did not show any statistically significant change: 1.9±1.6 (p=0.4). No eyes underwent additional glaucoma surgery in the study period.</p><p><strong>Conclusion: </strong>Canaloplasty combined with microtrabecular bypass stent surgery following cataract extraction demonstrated efficacy in reducing IOP and medication burden up to 24 months postoperatively. IOP reduction was also sustained up to 36 months postoperatively. The combined MIGS procedure is also effective in eyes with uncontrolled glaucoma.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"19 ","pages":"469-481"},"PeriodicalIF":0.0,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11829638/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143442947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retinal Artery Occlusion Associated with Prepapillary Arterial Loop: An Isolated Ocular Disease? Case Report and Literature Review.","authors":"Ahmad M Mansour, Maurizio Battaglia Parodi, Antônio Marcelo Barbante Casella, Wajiha J Kheir, Ziad Fayez Bashshur","doi":"10.2147/OPTH.S509248","DOIUrl":"https://doi.org/10.2147/OPTH.S509248","url":null,"abstract":"<p><strong>Purpose: </strong>When branch retinal artery occlusion is linked to prepapillary artery loop, is a systemic work-up necessary?</p><p><strong>Methods: </strong>Case Report and literature review. The databases searched were MEDLINE OVID, Scopus, Web of Science, and Embase. The search was for all relevant articles published from inception until October 31, 2024.</p><p><strong>Results: </strong>A total of 33 cases of prepapillary artery loop with retinal artery occlusion were reviewed. Median age at diagnosis was 24 years (range 10-64). Twenty five cases had no systemic disease while 9 had unrelated systemic disorder. Systemic workup was carried in 17 cases and was negative. The location of the branch retinal artery occlusion was inferior in 21 cases, superior in 6 cases, and combined superior and inferior in 2 cases. Paracentral acute middle maculopathy was noted in 2 cases. Precipitating factors included exercise in 4 cases, head trauma in 2 cases, blunt ocular trauma, severe sneezing, ocular rubbing and sun exposure in 1 case each.</p><p><strong>Conclusion: </strong>A branch retinal artery occlusion linked to a prepapillary loop appears as a distinct ocular condition in young healthy individuals. There is no definite need for additional diagnostic testing in such patients with a negative systemic history.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"19 ","pages":"449-458"},"PeriodicalIF":0.0,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11829647/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143443014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Three-Month Outcomes of SMILE Pro with the VISUMAX 800 for Myopic Astigmatism in a Large Population.","authors":"Hong Son Cung, Lan Huong Thi Tran, Thanh Ngoc Tran","doi":"10.2147/OPTH.S502915","DOIUrl":"10.2147/OPTH.S502915","url":null,"abstract":"<p><strong>Purpose: </strong>To report the visual and refractive outcomes of small-incision lenticule extraction (SMILE) Pro using a 2 MHz femtosecond laser for myopic astigmatism in a large population of Vietnamese patients.</p><p><strong>Methods: </strong>This was a retrospective clinical study of subjects that underwent keratorefractive lenticule extraction (KLEx) with the VISUMAX 800 at Hong Son Eye Hospital (Ha Noi, Vietnam) between June 2023 and October 2023. Primary outcome measures of monocular uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), and refraction, including vector analysis, were evaluated at 3-months postoperatively. Secondary outcome measures of intraoperative and postoperative complications were also recorded.</p><p><strong>Results: </strong>A total of 765 eyes from 389 patients (60.66% women, mean age of 23.54±5.20 years) were analyzed 3 months after surgery. The mean preoperative spherical equivalent refraction was -5.98±2.26 D. The postoperative spherical equivalent refraction was within ±0.50 D of the intended target in 81% and within ±1.00 D in 97% of eyes. The mean spherical equivalent refraction was -0.11±0.45 D. UDVA was 20/25 or better in 92% and 20/32 or better in 97% of eyes. The mean postoperative UDVA and CDVA values were 0.05±0.09 and 0.00±0.02 logMAR, respectively. There was no change in CDVA in 99% of eyes. Efficacy index was 0.92, and safety index was 1.00. One eye (0.13%) had a suction loss, which resulted in a lenticule remnant. No other complications were reported during surgery or the postoperative follow-up period.</p><p><strong>Conclusion: </strong>The current study, carried out on a large cohort of Asian patients, showed SMILE Pro with the VISUMAX 800 was safe and effective for treating myopic astigmatism.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"19 ","pages":"417-425"},"PeriodicalIF":0.0,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11812556/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143400926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Human Factors Studies to Assess the Usability of the Faricimab Prefilled Syringe.","authors":"Mark R Barakat, Henry M Kwong, Gelson Marcon, Olivia E O'Leary, Liliana P Paris, Petrick Schneider, Yannan Tang, Jordan M Graff","doi":"10.2147/OPTH.S503060","DOIUrl":"10.2147/OPTH.S503060","url":null,"abstract":"<p><strong>Purpose: </strong>Faricimab, the first bispecific antibody designed for intraocular use, is approved for the treatment of neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). Here, we report the usability of a novel faricimab 6 mg pre-filled syringe (PFS) configuration that has been designed specifically for intravitreal use.</p><p><strong>Patients and methods: </strong>A simulated-use human factors validation study enrolling 15 retina specialists and 15 ophthalmic assistants was conducted in a market research facility configured to represent an ophthalmology clinic. Participants' ability to complete tasks related to package handling, dose preparation, and injection of a faricimab 6 mg dose into a polymer eye using the PFS was assessed. In a second Phase 3b, single-arm, actual-use study, the ability of seven retina specialists and six ophthalmic assistants to prepare and administer the PFS in accordance with the instructions for use was assessed. Injections were performed into single eyes of 35 patients with nAMD or DME in three US clinics and patients were followed for 7 days for safety reporting (ClinicalTrials.gov identifier: NCT05569148).</p><p><strong>Results: </strong>In the simulated-use study, most retina specialists and ophthalmic assistants completed all tasks deemed essential for PFS preparation and administration correctly and without error. Of the 22 tasks, the pass rate was 86.7-100%; 16 tasks had a pass rate of 100%. No use errors were observed during the actual-use study. One patient experienced one mild adverse event of eye irritation that resolved the same day and was deemed unrelated to the study drug.</p><p><strong>Conclusion: </strong>Participants were able to safely and correctly prepare and administer a faricimab 6 mg dose using the PFS in accordance with the instructions for use, under realistic conditions representing the real world. The faricimab 6 mg PFS may therefore offer a more convenient, safe-handling alternative to vial administration.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"19 ","pages":"395-406"},"PeriodicalIF":0.0,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11809211/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143392693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Prospective, Crossover, Randomized, Double-Blind Clinical Study Comparing the Effectiveness and Ocular Comfort of 0.1% Hyaluronic Acid and 0.3% Hyaluronic Acid in Patients With Dry Eye Disease.","authors":"Seong-Jae Kim, Woong-Sun Yoo, Lee-Ha Kwon, Rock Bum Kim, Hyeon-Jeong Yoon, Kyung Chul Yoon","doi":"10.2147/OPTH.S489669","DOIUrl":"10.2147/OPTH.S489669","url":null,"abstract":"<p><strong>Purpose: </strong>Report the clinical effects and discomfort of using 0.1% hyaluronic acid (HA [Kynex 1^®, Alcon, Seoul, S. Korea]) and 0.3% HA (Kynex 3^®, Alcon, Seoul, S. Korea) to treat dry eye disease (DED).</p><p><strong>Methods: </strong>This study was designed as a prospective, crossover, randomized, and double-blind study. Patients aged >19 years with DED level 2 or higher, corneal staining score > 1, and tear break-up time (TBUT) < 10s were included. Sixty patients were randomly assigned to two groups. Patients in group 1 were instilled with 0.1% HA for four weeks and then 0.3% HA for the next four weeks. Group 2 patients were instilled with the eye drops in the reverse order of group 1. Patients were evaluated using a corneal staining score, TBUT, and the Standardized Patient Evaluation of Eye Dryness (SPEED) questionnaire at baseline, four weeks, and eight weeks.</p><p><strong>Results: </strong>In both groups, 0.3% HA showed an increasing trend in TBUT, although the difference was not statistically significant. Changes in the Schirmer test were greater in group 2, but this difference was also not statistically significant. The corneal staining score improved in both groups, with no statistically significant difference. While 0.3% HA was more effective than 0.1% HA according to the absolute value, this difference was not statistically significant. There was no difference between the two groups in the SPEED questionnaire evaluation that assessed aspects of discomfort, such as blurred vision, foreign body sensation, and burning sensation.</p><p><strong>Conclusion: </strong>0.3% HA was more effective for treating DED, although the difference was not statistically significant. In terms of discomfort, 0.3% HA showed no difference compared to 0.1% HA. Using both 0.1% HA and 0.3% HA in a tailored treatment approach can improve patient comfort and treatment outcomes.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"19 ","pages":"407-416"},"PeriodicalIF":0.0,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11809210/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143392686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An Electronic Frailty Index Based on Deficit Accumulation May Predict Glaucomatous Visual Field Progression.","authors":"Walter Duy, Nicholas Pajewski, Jeff D Williamson, Atalie C Thompson","doi":"10.2147/OPTH.S503177","DOIUrl":"10.2147/OPTH.S503177","url":null,"abstract":"<p><strong>Purpose: </strong>To investigate whether an electronic frailty index (eFI) is associated with visual field loss in glaucoma.</p><p><strong>Patients and methods: </strong>We identified 1163 subjects ≥65 years old with glaucoma (1082 right eyes and 1042 left eyes) who had a calculable baseline eFI, and who had reliable visual fields at baseline and final follow-up. Multivariable linear regression models adjusting for demographic and clinical variables were used to assess the association between eFI and mean deviation at baseline and the change in mean deviation over time in each eye.</p><p><strong>Results: </strong>Being pre-frail or frail was not associated with baseline MD, except in the right eye where being pre-frail was associated with a higher baseline MD. Increasing level of eFI was negatively correlated with change in MD (p<0.05 both eyes), but not baseline MD. Moreover, being frail was significantly associated with a more significant decline in MD in both eyes (Right eye: Beta -0.89, 95% CI (-1.71, -0.063), p=0.035; Left eye: Beta -1.25, 95% CI (-2.17, -0.34), p=0.007). Notably, baseline IOP was not associated with MD at baseline or the change in MD in the multivariable models.</p><p><strong>Conclusion: </strong>Glaucoma patients who are frail may be at higher risk of experiencing visual field decline, independent of baseline IOP. Future studies should investigate whether interventions to improve frailty can decrease risk of glaucoma progression.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"19 ","pages":"387-393"},"PeriodicalIF":0.0,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11807780/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143392689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Note on Literature Review Related to \"Oral Azithromycin Versus Oral Doxycycline in the Treatment of Meibomian Gland Dysfunction: A Systematic Review and Meta-Analysis\" [Letter].","authors":"Margarita Safir, Michael Mimouni, Dror Ben Ephraim Noyman","doi":"10.2147/OPTH.S513728","DOIUrl":"10.2147/OPTH.S513728","url":null,"abstract":"","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"19 ","pages":"371-372"},"PeriodicalIF":0.0,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11806671/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143383714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum: Early Real-World Patient and Staff Experience With an Intracanalicular Dexamethasone Insert [Corrigendum].","authors":"","doi":"10.2147/OPTH.S519248","DOIUrl":"https://doi.org/10.2147/OPTH.S519248","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.2147/OPTH.S448973.].</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"19 ","pages":"385-386"},"PeriodicalIF":0.0,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11807785/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143392691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hydrophobic and Hydrophilic IOLs in Patients with Uveitis - A Randomised Clinical Trial.","authors":"Sara Pålsson, Claes Schuborg, Bertil Sterner, Marita Andersson Grönlund, Madeleine Zetterberg","doi":"10.2147/OPTH.S493398","DOIUrl":"10.2147/OPTH.S493398","url":null,"abstract":"<p><strong>Purpose: </strong>To compare inflammatory response, visual acuity, and complications of two intraocular lenses (IOLs) in patients with and without uveitis.</p><p><strong>Setting: </strong>Tertiary referral centre at Sahlgrenska University Hospital/Mölndal, Sweden.</p><p><strong>Design: </strong>Prospective randomised controlled trial.</p><p><strong>Patients and methods: </strong>Patients with and without uveitis eligible for cataract surgery were randomised to receive a hydrophobic or a hydrophilic square-edged intraocular lens (IOL). Patients undergoing bilateral surgery received a hydrophobic IOL in one eye and a hydrophilic in the other. Visual acuity, flare, and central foveal thickness were used as outcome measures.</p><p><strong>Results: </strong>In total, 34 (61%) patients (52 eyes) with uveitis and 22 (39%) non-uveitic patients (38 eyes) were included in the study. Comparable corrected distance visual acuity (CDVA) was seen, regardless of IOL material. Flare, six months postoperatively, for those undergoing bilateral surgery, showed no significant difference between eyes receiving a hydrophilic IOL or a hydrophobic IOL; mean difference was -3.2 (SD ± 20.7) ph/ms between eyes with uveitis (p = 0.53) and -0.6 SD ± 7.5 ph/ms between eyes without uveitis (p = 0.77). No significant difference in cystoid macular edema (CME) was seen for uveitic patients receiving a hydrophobic IOL (n = 2; 8.0%) and those receiving a hydrophilic IOL (n = 6; 22.2%; p = 0.25).</p><p><strong>Conclusion: </strong>No significant differences in postoperative inflammatory reaction or rate of CME were seen regardless of using a hydrophobic or a hydrophilic IOL. In general, an improvement in CDVA was seen after cataract surgery with both types of IOLs. Thus, the present study did not support either of the IOL materials as advantageous in patients with uveitis.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"19 ","pages":"373-383"},"PeriodicalIF":0.0,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11806708/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143383644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validation of a Novel Low-Cost Glaucoma Risk Calculator for Community-Based Screening in High-Risk Populations.","authors":"Kara Grimes, Chisom T Madu, Carena Carrington, Daniel Laroche","doi":"10.2147/OPTH.S500509","DOIUrl":"10.2147/OPTH.S500509","url":null,"abstract":"<p><strong>Purpose: </strong>To assess the validity of a novel, low-cost glaucoma screening calculator in determining glaucoma risk in high-risk New York communities.</p><p><strong>Patients and methods: </strong>This prognostic community-based study was conducted in New York City neighborhoods from 2022 to 2024 among participants aged 40 years and older. Glaucoma screenings were held at community gatherings including local fairs, senior citizen homes, places of worship, and in the lobby of medical offices. The screenings were conducted by trained non-physician medical personnel comprised medical students and medical assistants working under physician supervision. Participants' intraocular pressure (IOP) and central corneal thickness (CCT) were measured in both eyes with a handheld tonometer and pachymeter, respectively. Participants then completed a comprehensive eye exam by an ophthalmologist to confirm glaucoma status. Statistical analysis was completed using MedCalc version 22.023 (MedCalc Software Ltd. Ostend, Belgium) with 95% confidence intervals.</p><p><strong>Results: </strong>Of the 823 study participants, 716 (mean age 62.9 ± 11.9 years) were eligible to participate and completed the comprehensive follow-up exam. 68% identified as Black, 6.7% identified as Hispanic/Latino, and 52.5% identified as female. The Laroche glaucoma calculator had a sensitivity of 93.5% (CI 89.1-96.5%), specificity of 91.3% (CI 88.5-93.6%), positive predictive value of 80.5% (CI 75.7-84.6%), negative predictive value of 97.3% (CI 95.5-98.4%) and accuracy of 91.9% (CI 89.6-93.8%).</p><p><strong>Conclusion: </strong>The Laroche glaucoma calculator shows high sensitivity, specificity, positive predictive value, negative predictive value, and accuracy using affordable screening methods to determine glaucoma risk.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"19 ","pages":"357-369"},"PeriodicalIF":0.0,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11804874/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143383794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}